CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- InVivo Therapeutics Holdings Corp. (NVIV) today announced the expansion of responsibilities for three members of its senior management team. The additional functional responsibilities, now at the senior management level, include Operations, Project Management, and Reimbursement Planning.
William D’Agostino, PE has been appointed Senior Vice President, Operations. Prior to his new responsibilities, he held the position of Vice President, Manufacturing & Engineering. Bill joined InVivo in September 2012. Previously, he held the position of Vice President, Engineering at Angiotech Pharmaceuticals which included running all product development and engineering activities across their international facilities. Bill also worked for Covidien for fifteen years where he gained extensive experience with the development, synthesis and clinical production of bioabsorbable polymers. He is a co-author of the book, Regulatory Strategies for Combination Products, published by PDA and DHI Publishing. Bill holds fourteen US and European patents for medical devices on which he co-invented. Bill is a Licensed Professional Engineer (PE) and holds an MBA from the University of Dallas and a BS in both Chemical Engineering and Materials Engineering from the University of Connecticut.
Kristin Neff has been appointed Vice President, Clinical Operations & Project Management. Previously, she held the position of Vice President, Clinical Operations. Kristin joined InVivo in August 2013 from TARIS Biomedical where she served as Senior Director, Clinical Operations. Prior to that, she was Vice President, Clinical Affairs at ConforMIS, Inc. and Director of Clinical Project Management at HeartWare, Inc. Kristin has an MS in Biomedical Engineering from Boston University and a BS in Electrical Engineering from UMass, Amherst. Kristin is a noted presenter at many conferences including Clinical Trials New England, Project Management Institute, Drug Information Association, and more.
Lisa Crockett has been appointed Vice President, Regulatory Affairs & Reimbursement Planning. Previously, she held the position of Vice President, Regulatory Affairs. Lisa joined InVivo in June of 2013 from Genzyme, where she most recently served as Associate Director of Regulatory Affairs. Lisa holds an MS in Regulatory Affairs from Northeastern University and a BS from Johnson and Wales University. Lisa is a part-time instructor in the Master’s Degree Program in Regulatory Affairs at Northeastern University.
All three members of the senior management team will report to CEO, Mark Perrin. Regarding these changes, Mark stated, “Following yesterday’s announcement of our new research and development strategy and the future direction of the company, it is critical to have these key functional responsibilities at the senior management level. Recognizing the valuable contributions that have been made by these three individuals, it is gratifying to have them assume such important additional responsibilities and is yet another example of the building and strengthening of our leadership team.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.